Cardiac PET Advanced Virtual Workshop (December 7-8, 2024)-Metabolic Imaging

Video Transcription

Video Summary

In this video, Panitia Charantaitui from the Mayo Clinic discusses metabolic imaging with PET (positron emission tomography). She provides an overview of FDG (F18 labeled fluorodeoxyglucose) and discusses its use in assessing myocardial viability, cardiac sarcoidosis, and other types of inflammation and infection in the heart. Panitia explains how FDG works and its role in tracing glucose exchange and metabolism in cells. She highlights the importance of FDG PET in identifying myocardial viability in patients with ischemic cardiomyopathy and reviews the protocols and interpretation of FDG PET images for viability assessment. Panitia also discusses the evidence supporting the use of FDG PET for viability assessment and its benefits in guiding revascularization decisions. Additionally, she explores the use of FDG PET in diagnosing and managing cardiac sarcoidosis and highlights its role in identifying large vessel vasculitis and cardiac infection. Panitia concludes by discussing the limitations and considerations for FDG PET in these various applications. The video provides a comprehensive overview of the use and interpretation of FDG PET in cardiac imaging. No credits were granted in the video.

Keywords

metabolic imaging

FDG PET

myocardial viability

cardiac sarcoidosis

ischemic cardiomyopathy

glucose metabolism

cardiac imaging